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Increasing dietary linoleic acid does not increase
tissue arachidonic acid content in adults
consuming Western-type diets:
a systematic review
Brian S Rett and Jay Whelan*

Abstract
Background: Linoleic acid, with a DRI of 12-17 g/d, is the most highly consumed polyunsaturated fatty acid in the
Western diet and is found in virtually all commonly consumed foods. The concern with dietary linoleic acid, being
the metabolic precursor of arachidonic acid, is its consumption may enrich tissues with arachidonic acid and
contribute to chronic and overproduction of bioactive eicosanoids. However, no systematic review of human trials
regarding linoleic acid consumption and subsequent changes in tissue levels of arachidonic acid has been
undertaken.
Objective: In this study, we reviewed the human literature that reported changes in dietary linoleic acid and its
subsequent impact on changing tissue arachidonic acid in erythrocytes and plasma/serum phospholipids.
Design: We identified, reviewed, and evaluated all peer-reviewed published literature presenting data outlining
changes in dietary linoleic acid in adult human clinical trials that reported changes in phospholipid fatty acid
composition (specifically arachidonic acid) in plasma/serum and erythrocytes within the parameters of our
inclusion/exclusion criteria.
Results: Decreasing dietary linoleic acid by up to 90% was not significantly correlated with changes in arachidonic
acid levels in the phospholipid pool of plasma/serum (p = 0.39). Similarly, when dietary linoleic acid levels were
increased up to six fold, no significant correlations with arachidonic acid levels were observed (p = 0.72). However,
there was a positive relationship between dietary gamma-linolenic acid and dietary arachidonic acid on changes in
arachidonic levels in plasma/serum phospholipids.
Conclusions: Our results do not support the concept that modifying current intakes of dietary linoleic acid has an
effect on changing levels of arachidonic acid in plasma/serum or erythrocytes in adults consuming Western-type
diets.

Background
Arachidonic acid (AA, 20:4 n-6) is a potent bioactive
molecule. When released from membrane phospholipids, it is converted to a variety of bioactive compounds,
called eicosanoids. These oxidized lipid molecules are
related to a number of chronic diseases including cardiovascular disease, cancer and inflammation [1-4].
Enrichment of AA in tissues is positively correlated with
* Correspondence: jwhelan@utk.edu
Department of Nutrition, University of Tennessee, Knoxville, Tennessee
37996-1900, USA

the production of eicosanoids. Linoleic acid (LA, 18:2
n-6) is the major dietary polyunsaturated fatty acid
(PUFA) in the Western diet and is a metabolic precursor to AA, linked biochemically via two desaturases and
an elongase. Typical intakes of LA are 12-17 grams per
day for women and men, respectively [5], or approximately 6% of energy. In the absence of other omega-6
(n-6) PUFA (including dietary AA), dietary LA is the
sole contributor to tissue AA. This relationship had
been established in experimental rodent models where
dietary LA was correlated with tissue AA content in a
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non-linear relationship in rats provided fat-free background diets [6] and lipid-rich diets [7].
Recent reviews suggest this relationship may exist in
adult humans consuming a typical Western-type diet
[8,9] and some have recommended limiting LA intake
as a way to help reduce tissue AA levels [10,11]. Certainly, this relationship had been reported in subjects
consuming diets containing LA at levels less than 2% of
energy [12]. There are, however, a number of recent
papers suggesting that increasing dietary LA does not
increase tissue AA levels, but in fact may have an
inverse relationship [13,14]. To compound the complexity of this relationship, the family of n-6 PUFA are, in
general, synonymously identified to dietary LA, while
seemingly ignoring other members who can contribute
to tissue AA, i.e., dietary gamma-linolenic acid (GLA,
18:3 n-6) and AA.
This study was designed to explore the relationship of
dietary LA and tissue AA, viz., phospholipid pools of
plasma/serum and erythrocytes. To our knowledge, this
is the first study to review the literature as to whether
increasing dietary LA is positively correlated with
increasing tissue AA content, and whether reducing
dietary LA has the opposite effect in adults consuming
Western-type diets. We further investigated what potential contributions other dietary n-6 PUFA may have on
tissue AA content. This study was limited in scope and
did not address other controversial issues related to
dietary LA or other PUFA or their effects on issues
related to health.

Methods
The aim of this paper was to identify, review, and evaluate all peer-reviewed published literature presenting data
outlining changes in dietary LA in adult human clinical
trials which report phospholipid fatty acid composition
(specifically AA) in plasma/serum and erythrocytes. We
chose the phospholipid pool in plasma/serum because
here is where a majority of the human data is, it represents membranes of lipoproteins derived from the surface of hepatic endoplasmic reticulum [15] (it helps to
control for potential variations in other components,
such as circulating triglycerides). The studies reporting
the fatty acid composition of erythrocyte phospholipids
do so because fatty acids in erythrocytes are almost
totally esterified in phospholipids. Further refinements
to the search strategy included reported changes in
tissue AA levels following dietary intake of AA and its
various n-6 PUFA precursors, i.e., LA and GLA. Published articles meeting eligibility criteria from 1970 to
present were reviewed, of which 4336 articles were
retrieved from May 2009 - November 2009 (Figure 1).
The primary search engine used was PubMed.gov (The
National Library of Medicine, National Institutes of
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Health), along with several prominent nutrition-based
clinical journals, i.e., American Journal of Clinical Nutrition, British Journal of Nutrition, and any additional
citations in articles reviewed. The search terms included
linoleic acid, g-linolenic acid, gamma-linolenic acid, arachidonic acid, omega-6, n-6, olive oil, soybean oil, sunflower oil, safflower oil, corn oil, omega-3, n-3, plasma,
erythrocyte, red blood cell and phospholipid.
The following eligibility criteria applied to all accepted
articles. Subjects had to be 18 years or older with no
known metabolic disorder that would influence tissue
AA content. Sufficient data on LA, GLA and/or AA
consumption (pre- and post-intervention) was required.
The nature of the intervention (i.e., capsules, oils or
dietary modifications) had to be presented. The fatty
acid data (plasma/serum and/or erythrocyte) had to be
determined from fasting patients, pre- and post-supplementation. Baseline and post-treatment of tissue phospholipid fatty acid composition had to be provided. On
occasion, percent changes in tissue fatty acid composition were provided and this data was used. Only those
papers published after 1970 due to improved gas chromatographic methods were accepted. Articles were automatically excluded if subjects were less than 18 years
old, pregnant or nursing, consuming supplements containing long chain n-3 fatty acids or supplemented fish
intake above and beyond their typical dietary regimen,
or using known inhibitors of AA metabolism, such as
non-steroidal anti-inflammatory drugs (NSAIDs).
After an initial review of the papers, 4043 were
excluded because of insufficient data or studies that
did not investigate our parameters. Of the 293 papers
that passed the initial review process, each was
reviewed by two independent investigators (BR and
JW) and thirty-six were acceptable by both reviewers.
Those papers that were not accepted (n = 249) were
rejected because baseline data was not sufficiently
reported, data for target tissues was not presented,
insufficient data was present and did not allow for
appropriate calculations, background diets were not
sufficiently described, or they included supplementation of restricted food items (i.e., long chain n-3
PUFA). Thirty-six articles were found to meet all of
the inclusion-exclusion criteria.
Once accepted, data on dietary n-6 fatty acid intake (%
of calories or g/d) and tissue AA content were extracted.
Study design, number and gender of subjects, method of
supplementation (i.e., type of oil, capsules or food component used) were recorded. Those studies involving
dietary LA as percentage of calories or g/d and its
effects on changes in tissue AA content are summarized
in Tables 1, 2, &3. Similarly, those studies involving
dietary GLA (0.36-6.00 g/d) and AA (0.50-6.00 g/d) are
summarized in Tables 4 and 5. If a study met the
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Articles retrieved from
electronic sources (ex.
PUBMED, AJCN, BJN etc..)
and references (4336)
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Articles not accepted due to
insufficient or missing data; or
otherwise not suitable for our research
objective (4043)

Articles that included baseline
diet and/or supplementation
amount and phospholipid data
(293)

Review of papers by two
reviewers for relevance and
inclusion (293)

Articles accepted (36)

Articles not accepted by both reviewers
because of design flaws, lack of
sufficient data for analysis/baseline
data not sufficiently reported, data for
target tissues not presented, insufficient
data describing n-6 supplementation,
supplementation of long chain n-3
PUFA/fish/fish oils, or based on
inclusion/exclusion criteria (249)

Figure 1 Schematic outlining the systematic review.

eligibility criteria and contained more than one comparison, each comparison was reported as a separate data
point.
Baseline tissue AA levels were defined as relative
abundance of AA in tissue phospholipids prior to dietary supplementation (or reduction) of the corresponding
dietary n-6 PUFA of interest (i.e., LA, GLA or AA). In
the case of cross-over designs, baseline fatty acid composition was established following a washout period or
after supplementation of a control diet if there were no
or only minor changes in the dietary n-6 PUFA content.
For example, a supplement rich in oleic acid (a monounsaturated fatty acid typically used as a control and
known to have a neutral effect on tissue AA content)
could be used as a control lipid (or oil) prior to supplementation of an equal amount of a lipid (or oil) rich in
LA. Percent change for each dietary n-6 fatty acid of

interest was used to standardize the relative differences
between baseline intakes and intervention intakes
following the experimental period using the following
formula:
intervention intake - baseline intake
× 100
baseline intake

The levels of intake were based on the relative caloric
amount (% of calories), and when this data was not
available absolute intake levels (g/d) were used. Percent
change for tissue AA content was used to standardize
the relative differences between baseline levels and intervention levels following the experimental period using
the following formula:
post - intervention level - baseline level
× 100
baseline level

Author,
(reference)
Lasserre [17]

Study design Subjects

Randomized
crossover

N = 24

Diet
length

Diet comparison

LA (% change)
Baseline to
intervention

ΔAA (%)
change

Comments

5 months

Peanut oil diet (baseline)
compared to milk fat diet

-90 (6.5%-0.6% )

9.99 N.S.

Used peanut oil group b/c close to DRI for LA. Subjects were nuns in
monastery.

Peanut oil diet (baseline)
compared to low erucic acid
rapeseed oil (canola oil) diet

-30 (6.5%-4.5%)

-5.49 N.S.

Used peanut oil group b/c close to DRI for LA. Subjects were nuns in
monastery.

Lichtenstein
[35]

Randomized
double-blind
crossover

N = 30

35 days

Soybean oil diet (baseline)
compared to high oleic acid
soybean oil diet

-82 (11%-1.9%)

-2.58 N.S.

Pooled data of men and women. Baseline diet of 10.96% energy
closest to DRI for LA. AA did not differ among remaining groups
tested either

Liou [37]

Randomized
crossover

N = 24

4 weeks

High linoleic acid sunflower oil
(diet) compared to high oleic
acid safflower oil (diet)

-63 (10.5%-3.8%)

-5.55 N.S.

Incorporated test oils into baked foods (cookies, breads), mayonnaise,
salad dressing. AA data presented in graphs, not tables. Fish intake
was avoided for all groups. AA PL content did not differ between
sequence of diets going from high LA to low LA or vice versa. Study
address low or high LA with constant ALA at 1%.

Goyens [38]

Double-blind
intervention

N = 19

6 weeks

Reduced LA in food items
(margarines, pastries, baked
goods)

-57 (7%-3%)

5.26 N.S.

Test oils consumed in margarine and pastries. Prohibited consumption
of fish or marine foods in all groups.

Vega-Lopez
[36]

Randomized
crossover

N = 15

35 days

Canola oil diet compared to
palm oil diet

-50 (6.5%-3.3%)

-8.06 N.S.

Canola oil in mixed foods was replaced by palm oil in mixed foods.
AA did not change among all three dietary groups. Canola oil diet is
baseline because closest to DRI LA intake.

Li [39]

Parallel
intervention

N = 17

28 days

High LA diet to moderate LA
diet using canola oil/canola
margarine

-48 (13.5%-7%)

-3.80 N.S

Subjects were given diet more than twice DRI for LA and then given
diet resembling the DRI for LA. All groups were asked to not consume
fish.

High LA diet to normal LA diet
using canola oil/canola
margarine

-39 (11.9%-7.3%)

-16.5 N.S.

Mantzioris
[40]

Parallel
intervention

N = 15

4 weeks

Control diet (sunflower oil)
group compared to
intervention diet (flaxseed oil)

-57 (7.8%-3.3%)

-4.5 N.S.

King [16]

Randomized
parallel

N = 66

6 weeks

Baseline diet compared to low
fat diet

-29 (10%-7.1%)

4.1 (p < 0.05)

Geppert [41]

Randomized
double- blind
intervention

N = 54

8 weeks

Baseline diet compared to LA
reduced diet (using olive oil
capsules)

-12 (5.8%-5.1%)

1.12 N.S.
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Table 1 Studies outlining the effects of decreasing dietary linoleic acid levels (% energy) from baseline on changes in plasma/serum phospholipid
arachidonic acid level

Control group consumed relatively close to DRI for LA while
intervention group reduced LA by more than half.
Used modified food items for diets containing different amounts of
fat. Reported AA PL in % change.
Used olive oil capsules with vegetarians.
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Percent change (±) from baseline in AA that is significant is identified with (p < 0.05). Percent change (±) from baseline in AA that is not significant is denotedby N.S.
Abbreviations: AA, arachidonic acid; DRI, Dietary Reference Intake; LA, linoleic acid; PL, phospholipid

Author,
(reference)

King [16]

Thijssen [42]

Montoya
[43]

Lichtenstein
[35]

Li [39]

Study
design

Diet comparison

LA (%
change)
Baseline to
intervention

Δ AA (%)
change

Comments

6 weeks

Baseline diet compared to moderate fat
diet

13 (10.3%1.6%)

-3.2 (p < 0.05)

Used modified food items for diets containing different
amounts of fat. Reported AA PL as % change.

5 weeks

Stearic acid diet to oleic acid diet in
food items (using margarines, breads,
sponge cakes)

14 (2.1%
-2.4%)

-2.24 (N.S.)

No order to diets given. Subjects received all 3 diets with
varying amounts of LA.

Oleic Acid to LA food items (margarines,
breads, sponge cakes)

287 (2.4%9.3%)

-1.15 (N.S.)

No order to diets given. Subjects received all 3 diets with
varying amounts of LA.

From palm oil based diet compared to
olive oil based diet

16 (3.2%-3.7%)

4.82 (N.S.)

Used nuns and priests. Everyone consumed same sequence of
diets. AA did not change among the three test diets. No
crossover, subjects were their own controls.

Olive oil based diet to sunflower oil base
diet

230 (3.7%12.2%)

-3.44 (N.S.)

Baseline soybean oil diet compared to
low saturated fat-soybean oil diet. The
soybean oils varied in LA composition

15.8 (11%
-12.7%)

0.89 (N.S.)

Baseline high oleic-soybean oil diet to
low ALA-soybean oil diet

552 (1.9%2.5%)

1.27 (N.S.)

Baseline Western diet to intervention diet
increased in LA intake using safflower oil

17.8 (10.1%11.9%)

6.18 (N.S.)

Used safflower oil/safflower margarine to increase LA in diet to
almost twice DRI of LA. AA did not differ among all groups in
study.

Baseline Western diet to intervention diet
increased in LA intake using safflower oil

82.4 (7.4%13.5%)

0.96 (N.S.)

Used safflower oil/safflower margarine to increase LA in diet to
more than twice DRI of LA. AA did not differ among all groups
in study.
Canola oil in mixed foods was replaced by soybean oil in mixed
foods. AA did not change among all three dietary groups.
Canola oil diet is baseline because close to the DRI for LA.

Subjects Diet length

Randomized N = 33
parallel
intervention
Randomized N = 45
multiple
crossover

Sequential N = 41
interventions

Randomized N = 30
double-blind
crossover

Parallel
N = 10
intervention N = 7

4 weeks

35 days

14 days 14
days
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Table 2 Studies outlining the effects of increasing dietary linoleic acid levels (% energy) from baseline on changes in plasma/serum phospholipid arachidonic
acid level

Pooled data of men and women. Five diets of random order.
Subjects visited metabolic kitchen 3 times week. Varying LA
amounts using modified soybean oils.

Vega-Lopez
[36]

Randomized N = 15
crossover

35 days

Canola oil diet compared to soybean oil
diet

64.2 (6.5%10.7%)

-2.35 (N.S.)

Liou [37]

Randomized N = 22
crossover

4 weeks

Low LA diet (high in oleic acid safflower
oil) compared to high LA diet (high in
sunflower oil)

176 (3.8%10.5%)

-0.18 (N.S.)

AA PL content presented as graphs, not numerically. Fish was
avoided in all dietary groups. ALA intake was kept constant
between low/high diet.

Valsta [19]

Randomized N = 39
crossover

6 weeks

Habitual diet compared to high LA
trisunflower oil diet

86 (4.2%-7.8%)

10 (p < 0.05)

Fish cut in half in all dietary groups. Has a baseline for before
each diet. Used trisunflower oil in margarine, food oil, salad
dressing, bread, cake and cookies, in place of habitual foods.

Habitual diet compared to high ALA
rapeseed oil diet

45 (4.2%-6.1%)

2.77 (N.S.)

Randomized N = 10
crossover

28 days

Low fat diet (20% energy) compared to
high fat diet (45% energy).

100 (6%-12%)

-16 (p < 0.05)

Modified foods rich in LA. Random order to diet, so baseline
was chosen based on DRI of LA. Used washout period of 21-28
days

Lasserre [17]

Randomized N = 24
crossover

5 months

Peanut oil diet compared to sunflower
oil

111 (6.5%13.7%)

-20 (p < 0.05)

Used peanut oil group b/c close to DRI for LA.

Innis [13]

Randomized N = 24
crossover

8 weeks

Low LA diet to high LA diet

176 (3.8%10.5%)

1.86 (N.S.)

Controlled for dietary AA.

Percent change (±) from baseline in AA that is significant is identified with (p < 0.05). Percent change (±) from baseline in AA that is not significant is denoted by N.S.
Abbreviations: ALA, alpha-linolenic acid; AA, arachidonic acid; DRI, Dietary Reference Intake; LA, linoleic acid; PL, phospholipid
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Table 3 Studies outlining the effects of supplementing dietary linoleic acid levels (g/day) on changes in plasma/serum
phospholipid arachidonic acid level
Author,
(reference)

Study design

Subjects

Diet
length

LA source, amount
supplemented (g/d)

Δ AA (%)
change

Comments

Anderson
[44]

Parallel intervention

N=8

3
months

Olive oil (0.2)

8.46 (N.S.)

Olive oil supplement

Olive oil (0.2)

9.05 (N.S.)

Provided LA for two different
groups

Oil blend (0.64)

3.38 (N.S.)

Different oil blends were
sources of LA

N=9
Thies [45]

Randomized, double-blind,
parallel intervention

N=8

12
weeks

Placebo oil (0.9)

5.25 (N.S.)

Geppert [21]

Randomized double- blind
parallel intervention

N = 20

8 weeks

Oil blend (0.86)

-7 (p < 0.05)

Blend palm, rapeseed and
sunflower oil

Johansson
[46]

Randomized, double-blind,
crossover

N = 12

4 weeks

Sea buckthorn berry oil
(0.90)

-2.2 (N.S.)

Sea buckthorn berry oil is
17.9% LA.

Kew [47]

Double-blind, parallel
intervention

N = 42

4 weeks

Olive oil (0.92)

-13.04 (N.S.)

Buckley [48]

Double-blind parallel
intervention

N = 45

4 weeks

Olive oil (0.95)

-7.14 (N.S.)

Yaqoob [34]

Randomized, double- blind
parallel intervention

N = 8 per
group

12
weeks

Placebo (coconut/soybean
oil) (1.0)

20 (N.S.)

Olive oil (1.2)

-2.1 (N.S.)

Sunflower oil (6.95)

16 (N.S.)

12
weeks

Oil blend (1.52)

-6.97 (N.S.)

Wallace [49]

Randomized, double- blind
parallel intervention

N=8

palm/soybean oil (1.7)

2.43 (N.S.)

Miles [27]

Randomized, double-blind
parallel intervention

N=8

12
weeks

Placebo (palm/sunflower oil)
(2.07)

2.19 (N.S.)

Grimsgaard
[20]

Double-blind, parallel
intervention

N = 78

7weeks

Corn oil (2.24)

3.1 (p <
0.05)

Conquer [50]

Double-blind, parallel
intervention

N = 24

42 days

Corn oil (2.39)

1.12 (N.S.)

Finnegan [51]

Double-blind, parallel
intervention

N = 50

6
months

Safflower/sunflower (11.6)

7.19 (N.S.)

N=8

Test oils provided as
margarine and capsules

Percent change (±) from baseline in AA that is significant is identified with (p < 0.05). Percent change (±) from baseline in AA that is not significant is denoted by N.S.
Abbreviations: AA, arachidonic acid; DRI, Dietary Reference Intake; LA, linoleic acid

Table 4 Studies outlining the effects of supplementing dietary gamma-linolenic acid on changes in plasma/serum
phospholipid arachidonic acid level
Author,
(reference)

Study design

Subjects

Diet
length

GLA source, amount
supplemented (g/d)

Δ AA (%)
change

Comments

Ebden [52]

Double-blind
intervention

N=6

8
weeks

Efamol oil (0.36)

6.1 (N.S.)

No crossover with placebo. Subjects were asthmatics
used medication or bronchodilator.

Thavonen
[29]

Randomized, doubleblind crossover

N = 15

3
weeks

Black current seed oil
(0.38)

3.7 (N.S.)

Subjects aged 55-75 years old

Theis [45]

Double-blind parallel
interventions

N=8

12
weeks

GLA-rich triacylglycerol
capsules (0.77)

27 (p <
0.05)

Subjects consumed capsules for 12 weeks. AA
changed only on 12th week.

Yaqoob
[34]

Double-blind parallel
intervention

N=8

12
weeks

Evening primrose oil
(1.06)

14 (N.S.)

Mills [28]

Randomized doubleblind parallel
intervention
Randomized doubleblind intervention
Pre-post intervention

N = 10

28
days

Borage oil (1.30)

12 (p <
0.05)

AA data available for only pre and post intervention
(28 days)

N = 8-12

12
weeks
3
weeks

Borage oil capsules
(2.00)
Ultra-GLA capsules
(6.00)

15 (p <
0.05)
31 (p <
0.05)

Consumed capsules for 12 weeks. AA only increased
after the 8th week, no difference after 8th week.

Miles [27]
Johnson
[53]

N=5

Percent change (±) from baseline in AA that is significant is identified with (p < 0.05). Percent change (±) from baseline in AA that is not significant is denoted by N.S.
Abbreviations: AA, arachidonic acid; GLA, gamma-linolenic acid
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Table 5 Studies outlining the effects of supplementing dietary arachidonic acid on changes in plasma/serum
phospholipid arachidonic acid level
Author,
(reference)

Study design

Subjects

Diet length

AA source, amount
supplemented (g/d)

Δ AA (%)
change

Comments

Sinclair [54]

Parallel intervention

N=4

7 days

White meat/eggs (0.50)

52 (p <
0.05)

Consumed AA rich, low fat diet

Ishikura [55]

Double-blind crossover

N = 25

1 month

SUNTGA40S capsules
(0.72)

27 (p <
0.05)

Derived from Mortierella alpina

Theis [45]

Randomized, double-blind,
parallel intervention

N = 48

12 weeks

ARASCO (0.68)

85 (p <
0.05)

Derived from Mortierella alpina

Kusmoto
[56]

Double-blind intervention

N = 12

4 weeks

SUNTGA40S (0.84)

45 (p <
0.05)

Derived from Mortierella alpina

Nelson [57]

Single blind crossover
intervention

N = 10

50 days

ARASCO (1.49)

85 (p <
0.05)

Had 65 day washout period.
Derived from Mortierella alpina

Seyberth
[58]

Single blind intervention

N=4

2-3 weeks,
depending upon
subject

Capsules, AA ethyl ester
(6.00)

136 (p <
0.05)

Averaged from all 4 subjects

Percent change (±) from baseline in AA that is significant is identified with (p < 0.05). Percent change (±) from baseline in AA that is not significant is denoted
by N.S.
Abbreviations: AA, arachidonic acid

Statistical Analysis

The overall linear correlation between percent change of
dietary n-6 fatty acids and percent change of tissue AA
was computed using the Proc Corr procedure in SAS
9.2 (SAS Institute Inc. SAS Campus Drive, Cary, North
Carolina). The correlation matrix and the T statistic
tested for correlation and statistical significance, respectively. For the linear correlations, the equation of the
line was computed, and represented by y = mx for those
that exhibited linearity. Data not resembling a linear
relationship (i.e. dietary GLA and AA) utilized a polynomial growth curve from SAS General Linear Model and
t-tests for model parameters tested for significance. Pvalues less than or equal to 0.05 were considered significant. The Y values represent changes of AA (% from
baseline) and the X values represent the changes of the
various dietary n-6 PUFA (% from baseline or g/d supplemented). In addition to the overall correlation test,
the statistical significance for each individual data point
(for changes in tissue AA), as reported by the authors in
their respective manuscripts, was identified in each
graph. If the changes from baseline were significantly
different the data was represented by triangle. If the
changes from baseline were not statistically different,
they were represented by a diamond.

Results
Eleven comparisons reported decreases in LA intakes
(-12% to -90%) and no significant correlations were
associated with changes in plasma/serum phospholipid
AA content (r2 = 0.07, p = 0.44, y = 0.026x) (Table 1
and Figure 2). Only one study of the eleven reported a
significant change, a 4.1% increase in AA content, following a 29% reduction in LA intake [16].

Increases in dietary LA, ranging from 12%-550%, was
not significantly correlated with changes in plasma/
serum phospholipid AA content (r2 = 0.074, p = 0.45, y
= -0.0053x) (Table 2 and Figure 3). Of the sixteen comparisons, only four studies reported significant changes
in AA levels when dietary LA levels were increased;
three studies reported 3-20% reductions following 12%110% increases in LA consumption [16-18] and only
one study reported a significant increase in AA content
(10%) following an 86% increase in LA intake [19]. Subdividing the studies by design (crossover versus noncrossover) had no effect on the results (data not shown).
Similarly, in those studies that only reported absolute
levels of LA supplementation (g/d), increasing LA supplementation was not significantly correlated with
changes in plasma/serum phospholipid AA content (r2
= 0.092, p = 0.64, y = 0.969x) (Table 3 and Figure 4). Of
the seventeen comparisons, only two were significantly
different, one resulted in an increase in AA content by
3% following supplementation of 2.24 g/d of LA [20]
and the other resulted in a reduction of AA content by
7% following supplementation of 0.86 g/d [21].
Similar comparisons were made in erythrocytes with
increasing and decreasing intakes of LA, although the
number of studies were more limited. Increases in dietary LA, ranging from 12%-100%, were not significantly
correlated with changes in tissue AA content (r2 = 0.06,
p = 0.75, y = -0.1479x) (Figure 5). Reducing dietary LA
intake (-12% to -70%) was not significantly correlated
with changes in tissue AA content (r2 = 0.017, p = 0.77,
y = -0.0174x) (Figure 6). In addition, out of the seven
studies, only one study reported a significant change
where decreasing dietary LA intake by 29% resulted in a
4% increase in AA content [16].
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Figure 2 Effects of decreasing dietary linoleic acid (LA) intake (% change) based on energy on changes in plasma/serum phospholipid
arachidonic acid (AA) content. Significant changes (p < 0.05) in AA as reported in the original papers are designated as triangles. Non-significant
AA changes as reported in the original papers are designated as diamonds. Abbreviations: AA, arachidonic acid; LA, linoleic acid; PL, phospholipid.
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arachidonic acid (AA) content. Significant changes (p < 0.05) in AA as reported in the original papers are designated as triangles. Nonsignificant AA changes as reported in the original papers are designated as diamonds. Abbreviations: AA, arachidonic acid; LA, linoleic acid; PL,
phospholipid.
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Figure 4 Effects of increasing dietary linoleic acid (LA) intake (g/d) on changes in plasma/serum phospholipid arachidonic acid (AA)
content. Significant changes (p < 0.05) in AA as reported in the original papers are designated as triangles. Non-significant AA changes as
reported in the original papers are designated as diamonds. Abbreviations: AA, arachidonic acid; LA, linoleic acid; PL, phospholipid.
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Figure 5 Effects of increasing dietary linoleic acid (LA) (% change) intake based on energy on changes in erythrocyte (RBC)
phospholipid arachidonic acid (AA) content. Significant changes (p < 0.05) in AA as reported in the original papers are designated as
triangles. Non-significant AA changes as reported in the original papers are designated as diamonds. Abbreviations: AA, arachidonic acid; LA,
linoleic acid; PL, phospholipid.
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Figure 6 Effects of decreasing dietary linoleic acid (LA) (% change) based on energy on changes in erythrocyte (RBC) phospholipid
arachidonic acid (AA) content. Significant changes (p < 0.05) in AA as reported in the original papers are designated as triangles. Nonsignificant AA changes as reported in the original papers are designated as diamonds. Abbreviations: AA, arachidonic acid; LA, linoleic acid; PL,
phospholipid.

Seven studies met our criteria for the effects of GLA
supplementation on changes in plasma/serum phospholipid AA content (Table 4 and Figure 7). There appeared
to be a dose dependent increase in AA content with
increasing intakes of GLA (ranging from 0.36 g/d to 6.00
g/day). This positive correlation (r2 = 0.75, p = 0.03, y =
0.004x + 7.36) was significant with a linear regression
model, and approached significance with a non-linear
(quadratic) regression model (r 2 = 0.56, y = -1.4x 2 +
13.76x, p = 0.079). The number of available data may be
a factor in these results. Of the six GLA data points, four
of them reported statistically significant increases in AA.
Similiarly, increasing dietary AA (0.50 g/d to 6.00
g/day) was positively correlated with increases in
plasma/serum phospholipid AA content using a quadratic regression model (r 2 = 0.79, y = -8.7x 2 + 74.87x,
p = 0.013) (Figure 8). All data points were reported as
significantly different (Table 5).

Discussion
Arachidonic acid is arguably the most important PUFA
associated with membrane phospholipids. Upon release,
AA can be enzymatically metabolized to a myriad of
bioactive derivatives, eicosanoids, known to contribute
to a variety of chronic diseases, but are also known to
be involved in tissue homeostasis and the resolution of
inflammation [1-4,22]. The relative abundance of AA in
membrane phospholipids positively influences eicosanoid production [23]. It is well known that dietary
PUFA can affect tissue AA levels; however, what is
uncertain and controversial is whether modifying current intakes of dietary LA will result in concomitant
changes in tissue AA content, i.e., increasing LA intake
results in an increase in tissue AA content and decreasing LA has the opposite effect [8]. The goal of this
paper was to ascertain the relationship between dietary
LA and tissue AA content (phospholipid pools of
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Figure 7 Effects of increasing dietary gamma-linolenic acid (GLA) (g/d) on changes in plasma/serum phospholipid arachidonic acid
(AA) content. Significant changes (p < 0.05) in AA as reported in the original papers are designated as triangles. Non-significant AA changes as
reported in the original papers are designated as diamonds. Abbreviations: AA, arachidonic acid; GLA, gamma-linolenic acid; PL, phospholipid.

plasma/serum and erythrocytes) in adults consuming a
Western-style background diet. It was not designed to
address other controversies surrounding the issues of
dietary n-6 or n-3 PUFA or in other population groups.
Many papers interchange the more general term n-6
PUFA for dietary LA, but there are two major n-6
PUFA, LA and AA, that are distributed unevenly in the
Western diet. While LA is the major PUFA in most
commonly consumed foods, AA is exclusively found in
animal products, such as, muscle, organ meats and eggs
[24]. They have distinct biological activities that are biochemically linked via desatuation and elongation, and as
such, LA is the conditionally essential fatty acid. Linoleic
acid is specifically required in the skin to maintain the
integrity of the epidermal water barrier and AA is the
immediate precursor to eicosanoids, as well as being the
n-6 PUFA selectively incorporated into the membranes
of certain tissues, i.e., brain [25]. When consumed (LA
vs. AA), they appear to have differential effects on tissue
fatty acid composition, where AA appears to more
robustly modify tissue AA levels and eicosanoids [14,26].
The data presented in this paper suggests that a dose
response between dietary LA and tissue AA does not

exists within the backdrop of individuals consuming a
Western-type diet. Increasing LA by as much as 551%
from baseline and reducing LA by as much as 90% from
baseline failed to yield compelling evidence supporting
the concept that any conversion of dietary LA to downstream metabolites results in tissue enrichment of AA, a
notion commonly assumed. For example, “However,
the higher concentrations of LA typically found in the
Western diet results in a greater conversion of LA to arachidonic acid” [8] and“Excessive n-6 precursors promotes
formation of AA” [9], suggesting enrichment of AA in
tissues with increases in LA intake. We chose to evaluate the data by looking at changes from baseline in
tissue AA content to standardize the data from one
study to the next. Each study began with a baseline
value and we reported percent changes from that baseline. Supplemental intakes of LA were reported based
on energy and when that value could not be determined,
we reported absolute supplemented values, and these
data were reported seperately.
As observed from the distribution of the responses,
there was wide variability. Some papers showed small
increases in tissue AA levels when dietary LA changed,
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Figure 8 Effects of increasing dietary arachidonic acid (AA) (g/d) based on energy on changes in plasma/serum phospholipid AA
content. Significant changes (p < 0.05) in AA as reported in the original papers are designated as triangles. Non-significant AA changes as
reported in the original papers are designated as diamonds. Abbreviations: AA, arachidonic acid; PL, phospholipid.

while other papers showed small decreases, but most of
these changes lacked significance. When there was significance, the changes were minimal and the distribution
pattern of the data did not favor an increase or a
decrease. We chose plasma/serum and erythrocytes as
the tissues of choice because here is where the bulk of
data exists in the human literature. Erythrocytes represent a more stable pool of dietary lipids, contain very little neutral lipids and thus represents a membrane
fraction of AA. Fasting plasma/serum phospholipid
levels primarily (but not exclusively) represents in part
phospholipids of lipoproteins that are derived from
hepatic endoplasmic reticulum [15], and this pool is
more responsive to more recent dietary PUFA intakes.
In an effort to identify why dietary LA may not modify
tissue AA levels, we reviewed the literature for dietary
GLA using the same search strategy. Was the conversion of LA to AA rate-limiting, or were tissue levels of
AA saturated? Delta-6 desaturase is the rate-limiting

enzyme in the metabolism of LA to AA. GLA is a dietary n-6 PUFA that enters the metabolic pathway after
the delta-6 desaturase step. If delta-6 desaturase is ratelimiting and tissue AA content is not saturated, then
there should be evidence that including GLA in the diet
increases tissue AA levels. When GLA was supplemented as the triacylglycerol form or as a component of a
dietary oil containing GLA (i.e., blackcurrant, evening
primrose or borage oil), tissue AA content increased in
a dose responsive manner. These effects appeared to be
less prominent in those studies [27-29] that used oils
containing appreciable amounts of the more highly
unsaturated n-3 PUFA stearidonic acid, i.e., blackcurrant
[30]. When AA was supplemented in the diet, there was
further enrichment in tissue AA content above that
observed with either LA or GLA. These results suggest
that delta-5 desaturase potentially becomes rate limiting
when GLA is supplemented. The reaction mediated by
delta-5 desaturase is an intermediate step between GLA
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and AA and by-passing that step with dietary AA leads
to further enrichment. These data seem to suggest that
while dietary LA maybe a metabolic precursor for AA,
its influence on tissue levels in populations consuming
Western diets are limited by the enzymatic conversion
through delta-6 desaturase and not due to tissue saturation of AA. These data are supported by the poor rates
of conversion of plasma/serum LA to AA in adults. In
tracer studies involving stable isotopes, the estimated
fractional conversion of LA to AA was between 0.3%
and 0.6% [31].
The levels of LA in the diet required to achieve essentiality could be as low as 0.5-2.0% of energy in infants
[32,33] and it has been reported that tissue levels of AA
no longer respond to dietary LA intakes above 2%
energy in adults [12]. Our study was designed to chose
studies that incorporated a Western-type diet where LA
is not typically limiting, reflective of the general public.
This means a full compliment of PUFAs were being
consumed along with LA supplementation. The DRIs
for LA and alpha-linolenic acid (ALA, 18:3 n-3) are 12
g-17 g/d and 1.1 g-1.6 g, respectively (women the lower
figure, men the higher figure). This would be equivalent
to intakes approximating 6% and 0.7% of calories per
day for LA and ALA, respectively. It is not unreasonable
to think that with a background diet containing LA,
ALA, AA, and long-chain n-3 PUFAs, i.e. eicosapentaenoic acid (EPA, 20:5 n-3) and docosahexaenoic acid
(DHA, 22:6 n-3) at typical intakes, that modifying dietary LA levels may not influence tissue AA levels. It is
possible that as LA increases in the diet it maybe competing with AA for reacylation into phospholipids
[13,14,16-18,21,34].
A small number of studies modified LA intakes by
using oils that also contained some ALA, such as soybean and canola oil [17,35,36], but the results from
these studies were not significant and were similar to
the other results. There could be some concern that
some of the supplemented oils contain ALA, such as
soybean oil. It must be remembered that soybean oil has
a LA:ALA ratio similar (8:1) to that found in the US
diet (10:1) and if you included or excluded these papers
the results were unaffected. We also included two
studies that supplemented LA with recommended fish
restrictions (because they met our inclusion/exclusion
criteria) [19,37]. One study (+176% LA) reported no
changes in AA levels, while the other (+86% LA)
reported a 10% increase in AA.
Some of the weaknesses of this review are reflected in
the studies that qualified for our evaluation. Most were
not designed to specifically address our research question; however, those that were specifically designed to
evaluate the effect of dietary LA on tissue AA content
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yielded results that were similar to the overall results
[13]. Each study used a different population with potentially different background diets, but overall this would
better reflect the consumption patterns of the general
public. Not all studies were blinded (61% were blinded)
and dietary LA was not exclusively modified. The methods for modifying LA intakes were varied and other
dietary PUFA were not controlled for with the exceptions identified previously, and data for only two tissues
were evaluated. When LA was modified, it was done so
by typically changing the levels of an oil rich in LA (i.e.,
corn oil, safflower oil, sunflower oil) or foods containing
LA (as opposed to adding pure LA), reflecting how LA
would be consumed by the general public. There were no
standard length to the studies. For example, studies
involving plasma/serum ranged between 14 days-5
months, and those looking at erythrocyte data ranged
between 14-180 days. Importantly, the subjects were used
as their own controls, the studies addressed changes in
LA in relationship to Western-type diets, and the results
were not different between those studies that were double-blind randomized placebo controlled trials (1/3) and
those that were not. Despite these weaknesses, positive
results were still identified with intakes of GLA and AA,
helping to support those results reported with LA.

Conclusions
Elevated tissue AA levels are believed to be positively
associated with eicosanoid formation and risk for a variety of chronic diseases, including cardiovascular disease,
cancer and inflammation. The literature expresses concern over the fact that increasing dietary LA can potentially enrich tissues with AA due to their metabolic link.
The results of this study do not support this concern.
Whereas AA levels in blood phospholipids is increased
by GLA or AA supplements, intervention studies bring
no evidence to suggest that changes in dietary LA will
modify tissue AA content in an adult population consuming a Western-type diet.
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